ArticleFrontiers in microbiology2020
NopD of
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Type III effectors of symbiotic Rhizobia include diverse predicted transcriptional and post-transcriptional modulators.PLoS biology · 2026Article
- Silenced cutters: mechanisms and effects of protease inhibition in plant-pathogen interactions.Journal of experimental botany · 2025Review
- Diversity of bradyrhizobial T3SS systems and their roles in symbiosis with peanut (Applied and environmental microbiology · 2025Article
- The rhizobial type III effectors ErnA and Sup3 hijack the SUMOylation pathway to trigger nodule formation in Aeschynomene species.The New phytologist · 2025Article
- Putative type III effector SkP48 of Bradyrhizobium sp. DOA9 encoding a SUMO protease blocks nodulation in Vigna radiata.Scientific reports · 2025Article
- Pangenome analysis indicates evolutionary origins and genetic diversity: emphasis on the role of nodulation in symbioticFrontiers in plant science · 2025Article
- A new type III effector from Bradyrhizobium sp. DOA9 encoding a putative SUMO-protease blocks nodulation in Arachis hypogaea L.Scientific reports · 2024Article
- Broad-spectrum ubiquitin/ubiquitin-like deconjugation activity of the rhizobial effector NopD from Bradyrhizobium (sp. XS1150).Communications biology · 2024Article
- Differential symbiotic compatibilities between rhizobium strains and cultivated and wild soybeans revealed by anatomical and transcriptome analyses.Frontiers in plant science · 2024Article
- NopAA and NopD Signaling Association-Related GeneInternational journal of molecular sciences · 2023Article
- G-type receptor-like kinase AsNIP43 interacts with rhizobia effector nodulation outer protein P and is required for symbiosis.Plant physiology · 2023Article
- Effector-Dependent and -Independent Molecular Mechanisms of Soybean-Microbe Interaction.International journal of molecular sciences · 2022Review
- The Rhizobial Type 3 Secretion System: The Dr. Jekyll and Mr. Hyde in the Rhizobium-Legume Symbiosis.International journal of molecular sciences · 2022Review
- Effector-triggered inhibition of nodulation: A rhizobial effector protease targets soybean kinase GmPBS1-1.Plant physiology · 2022Article
- Article
- The Type III Effectome of the SymbioticBiomolecules · 2021Article
- Use of the rhizobial type III effector gene nopP to improve Agrobacterium rhizogenes-mediated transformation of Lotus japonicus.Plant methods · 2021Article
- SUMOylation in Phytopathogen Interactions: Balancing Invasion and Resistance.Frontiers in cell and developmental biology · 2021Review
- Multiple Domains in the Rhizobial Type III Effector Bel2-5 Determine Symbiotic Efficiency With Soybean.Frontiers in plant science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effectors secreted by the type III protein secretion system (T3SS) of rhizobia are host-specific determinants of the nodule symbiosis. Here, we have characterized NopD, a putative type III effector of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.